US Patent 11085079 Universal Sanger sequencing from next-gen sequencing amplicons
Patent 11085079 was granted and assigned to Quest Diagnostics on August, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+235 characters)
Article
Patent abstract
Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110850790
Date of Patent
August 10, 2021
0Patent Application Number
201810260
Date Filed
October 26, 2018
0Official Website
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110850790
Date of Patent
August 10, 2021
0Patent Application Number
201810260
Date Filed
October 26, 2018
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11085079 Universal Sanger sequencing from next-gen sequencing amplicons
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11085079
Date of patent
August 10, 2021
Patent application number
20181026
Date Filed
October 26, 2018
Find more entities like US Patent 11085079 Universal Sanger sequencing from next-gen sequencing amplicons
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.